Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Collaboration leverages ... and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

Pfizer is partnering with Flagship Pioneering to combine ... Flagship Pioneering’s president of pioneering medicines and managing partner Paul Biondi said, “Autoimmune diseases impose a substantial ...